Previous 10 |
SAN DIEGO , Sept. 14, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...
Cardiff Oncology (NASDAQ: CRDF ) : Q2 GAAP EPS of -$0.51 misses by $0.27 . More news on: Cardiff Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Aug. 11, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castrate-resistant p...
SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resis...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
Cardiff Oncology Inc. Website:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...